Traws Pharma vs Xenetic Biosciences
TRAW and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TRAW and XBIO compare
Traws Pharma and Xenetic Biosciences are about the same size, with market caps of $3.9M and $3.9M.
Xenetic Biosciences scores higher on the StockData Score (10 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TRAW | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $3.9M | $3.9M |
| Share price | $0.251 | $1.66 |
| Change, 1 year | −88.3% | −37.1% |
| Change, 5 years | −99.7% | −88.8% |
| Beta (5Y) | 1.19 | 0.87 |
| Employees | 7 | 2 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.3× |
| P/B | – | 0.9× |
| Fair value | – | $3.65 |
| Margin of safety | – | 54.5% |
| Growth | ||
| Revenue growth (TTM) | – | 3.5% |
| Revenue growth, 5Y average | 64.6% (better) | 46.8% |
| Profitability | ||
| Operating margin | – | −130% |
| Net margin | – | −124% |
| Return on equity | – | −87.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.93 | 3.15 (better) |
| Altman Z-score | −85.39 | −44.51 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −109% | – |
| Shareholder yield | −109% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 40.1% | 6.5% |
| Held by insiders | 35.7% | 12.2% |
| Insider net buying, 12 months | $998K | – |
| Short interest, % of float | 6.9% | 1.8% |
Go deeper
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.